Literature DB >> 19102722

Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.

Lois Hinman1, Brian Spear, Zenta Tsuchihashi, James Kelly, Peter Bross, Federico Goodsaid, Francis Kalush.   

Abstract

The 4th US FDA/Industry Workshop on Pharmacogenomics in Drug Development and Regulatory Decision Making, was held in MD, USA, on December 10-12, 2007. One of the breakout sessions of the workshop focused on the regulatory issues around codevelopment of drugs and companion diagnostics. This session used hypothetical case studies as focal points for discussion of current thought and critical issues for both industry and the FDA in this evolving field. The panel and the audience discussed the evolution of the FDA's thinking on the regulatory path for companion diagnostics since the release of the April 2005 draft Drug Test Codevelopment Concept Paper and the issues faced by industry in attempting codevelopment efforts. This session provided an opportunity to allow an exchange of ideas between the FDA and industry and to identify critical issues that need further discussion in this important and evolving field.

Mesh:

Year:  2009        PMID: 19102722     DOI: 10.2217/14622416.10.1.127

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  2 in total

1.  Drug development in pediatric psychiatry: current status, future trends.

Authors:  John S March; Joerg M Fegert
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-02-07       Impact factor: 3.033

2.  A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.

Authors:  Dee Luo; James A Smith; Nick A Meadows; A Schuh; Katie E Manescu; Kim Bure; Benjamin Davies; Rob Horne; Mike Kope; David L DiGiusto; David A Brindley
Journal:  Front Genet       Date:  2016-01-28       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.